John Tyerman
Partner, Head of Corporate, UK
Helping our clients grow and mitigate risk throughout their life-cycle is what we do best. Our international sector focussed Corporate Group is divided into core practice areas: mergers & acquisitions, equity capital markets and private equity.
Our advisers act on domestic and international matters of all shapes and sizes, working with many of the leading names in the market. Browse our experience below, or use the filters to look-up recent work in particular geographies and industry sectors.
Our expertise, at your disposal
With over 430 partners and 3000 people around the world, we are well-placed to support you across a full range of legal and advisory services.
This session will focus on the Impact of Brexit on how sport does business – providing what business needs to know.
This session will take an in-depth look at the current market, the trends and themes arising in financing and investing in sport with guidance from our industry leaders on key issues.
In this session, our market leading team provide their insight into the current key issues and challenges facing the industry with solutions and practical guidance on employment, contracts, immigration, regulation, dispute resolution and the impact of Brexit.
This session will cover how sport can build on bringing back live events, the return of spectators and the likely changes needed both temporary and permanent on how events and venues are organised and operated.
Multinational law firm Pinsent Masons has advised NTR PLC on the acquisition of a 54MW portfolio of co-located solar and battery storage projects in County Wexford, Ireland, from renewable energy developer RES.
Multinational law firm Pinsent Masons has advised propco investor LDC Care Homes and its asset and investment manager Elevation Advisors on the migration of a care homes portfolio from Four Seasons Health Care Group (FSHC) to new operators.
Multinational law firm Pinsent Masons has advised Teva Pharmaceuticals’ subsidiary, Actavis Group PTC, on the successful €84m sale of a suite of consumer healthcare products to Karo Pharma AB (Karo).